312 related articles for article (PubMed ID: 26954459)
1. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
Lin F; Li Z; Hua Y; Lim YP
Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
[TBL] [Abstract][Full Text] [Related]
2. Oncoproteomics: Trials and tribulations.
Zhou L; Li Q; Wang J; Huang C; Nice EC
Proteomics Clin Appl; 2016 Apr; 10(4):516-31. PubMed ID: 26518147
[TBL] [Abstract][Full Text] [Related]
3. Proteomics of ovarian cancer: functional insights and clinical applications.
Elzek MA; Rodland KD
Cancer Metastasis Rev; 2015 Mar; 34(1):83-96. PubMed ID: 25736266
[TBL] [Abstract][Full Text] [Related]
4. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
[TBL] [Abstract][Full Text] [Related]
5. Predicting cancer drug response by proteomic profiling.
Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathway activation - New type of biomarkers for tumor morphology and personalized selection of target drugs.
Buzdin A; Sorokin M; Garazha A; Sekacheva M; Kim E; Zhukov N; Wang Y; Li X; Kar S; Hartmann C; Samii A; Giese A; Borisov N
Semin Cancer Biol; 2018 Dec; 53():110-124. PubMed ID: 29935311
[TBL] [Abstract][Full Text] [Related]
7. Towards defining biomarkers indicating resistances to targeted therapies.
Stehle F; Schulz K; Seliger B
Biochim Biophys Acta; 2014 May; 1844(5):909-16. PubMed ID: 24269379
[TBL] [Abstract][Full Text] [Related]
8. Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact.
Coleman O; Henry M; McVey G; Clynes M; Moriarty M; Meleady P
Expert Rev Proteomics; 2016; 13(4):383-94. PubMed ID: 26985644
[TBL] [Abstract][Full Text] [Related]
9. [Proteome analysis--basis for individualized pancreatic carcinoma therapy?].
Löhr JM; Faissner R; Findeisen P; Neumaier M
Internist (Berl); 2006 Jun; 47 Suppl 1():S40-8. PubMed ID: 16773365
[TBL] [Abstract][Full Text] [Related]
10. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
Tsimberidou AM
Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
[TBL] [Abstract][Full Text] [Related]
11. Drug-biomarker co-development in oncology - 20 years and counting.
Twomey JD; Brahme NN; Zhang B
Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
[TBL] [Abstract][Full Text] [Related]
12. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
13. Cancer proteomics and its application to discovery of therapy response markers in human cancer.
Smith L; Lind MJ; Welham KJ; Cawkwell L;
Cancer; 2006 Jul; 107(2):232-41. PubMed ID: 16752413
[TBL] [Abstract][Full Text] [Related]
14. Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.
Ali M; Khan SA; Wennerberg K; Aittokallio T
Bioinformatics; 2018 Apr; 34(8):1353-1362. PubMed ID: 29186355
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy in cancer.
Tsimberidou AM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
[TBL] [Abstract][Full Text] [Related]
16. Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View.
Dar KB; Bhat AH; Amin S; Anjum S; Reshi BA; Zargar MA; Masood A; Ganie SA
Curr Cancer Drug Targets; 2019; 19(6):430-448. PubMed ID: 30073927
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective.
van Dijk AD; de Bont ESJM; Kornblau SM
Expert Rev Proteomics; 2020 Jan; 17(1):1-10. PubMed ID: 31945303
[No Abstract] [Full Text] [Related]
18. Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer.
Li XH; Li C; Xiao ZQ
J Proteomics; 2011 Nov; 74(12):2642-9. PubMed ID: 21964283
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring of targeted anticancer therapy.
Decosterd LA; Widmer N; Zaman K; Cardoso E; Buclin T; Csajka C
Biomark Med; 2015; 9(9):887-93. PubMed ID: 26333311
[TBL] [Abstract][Full Text] [Related]
20. Prediction of individual response to anticancer therapy: historical and future perspectives.
Unger FT; Witte I; David KA
Cell Mol Life Sci; 2015 Feb; 72(4):729-57. PubMed ID: 25387856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
